Understanding the needs of Stage III melanoma patients when choosing treatments.
28 July 2021
Ann Livingstone, a researcher at The University of Sydney, seeks people with Stage III melanoma who have completed their surgery to participate in a 20-minute online survey regarding their views about immunotherapy. Immunotherapy drugs include nivolumab (Opdivo), pembrolizumab (Keytruda), or ipilimumab (Yervoy).
Treatment for melanoma involves surgery to remove it and can be followed by extra (adjuvant) immunotherapy, a type of drug that uses the body’s immune system to fight any leftover melanoma cells. Immunotherapy has proven to be life-saving for 50% of advanced melanoma patients, however it can have downsides and side-effects. This research will help understand if the benefits of the treatment, including the potential to live longer, outweigh the downsides.
Please help us understand what is most important to patients when choosing melanoma treatments.
If you have been diagnosed with Stage III melanoma and are willing to share your views about immunotherapy, please click this link to complete the online survey. Please note, you can participate as a stage III melanoma survivor or current patient, and you don’t need need to have had immunotherapy to take part.
Please do not hesitate to contact Ann with any questions via email at firstname.lastname@example.org or phone 0421 865 113.
Melanoma Institute Australia is affiliated with The University of Sydney.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.